Older heart failure patients with no immediate family are especially vulnerable. Additional interventions may be necessary to reach these patients and provide the best care possible.

Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.

ACC President Christopher Kramer, MD, testified before a Congressional subcommittee to ask for federal funding to support a new law aimed at reducing sudden cardiac arrest deaths, and to support NIH research.

The late-breaking five-year results of the Evolut Low-Risk Trial presented at the American College of Cardiology (ACC) 2025 meeting in late March, showed positive results for the Evolut transcatheter aortic valve replacement (TAVR) system vs. surgical aortic valve replacement (SAVR). 

ACC Immediate Past President Cathie Biga spoke to Cardiovascular Business about some of the challenges healthcare faces in the wake of mass layoffs and significant funding cuts put in place by the Trump administration.